News
OPTEY
0.106
NaN%
--
Weekly Report: what happened at OPTEY last week (1124-1128)?
Weekly Report · 4d ago
Weekly Report: what happened at OPTEY last week (1117-1121)?
Weekly Report · 11/24 09:05
Weekly Report: what happened at OPT last week (1110-1114)?
Weekly Report · 11/17 09:05
Opthea Limited Announces Successful AGM Results
TipRanks · 11/12 14:05
Opthea Limited held its Annual General Meeting
Reuters · 11/11 00:22
Weekly Report: what happened at OPT last week (1103-1107)?
Weekly Report · 11/10 09:05
Weekly Report: what happened at OPT last week (1027-1031)?
Weekly Report · 11/03 09:05
Opthea to Delist from Nasdaq on November 19
Reuters · 10/30 12:01
Opthea Appoints Hamish George As CFO
NASDAQ · 10/27 11:40
Weekly Report: what happened at OPT last week (1020-1024)?
Weekly Report · 10/27 09:05
Weekly Report: what happened at OPT last week (1013-1017)?
Weekly Report · 10/20 09:05
Weekly Report: what happened at OPT last week (1006-1010)?
Weekly Report · 10/13 09:05
Opthea Limited Schedules Virtual Annual General Meeting for November 2025
Barchart · 10/11 05:38
Opthea Limited announces date for annual general meeting
Reuters · 10/10 10:03
Opthea Limited Secures A$10.8 Million Australian R&D Tax Incentive to Advance Sozinibercept Development
Reuters · 10/06 10:03
Weekly Report: what happened at OPT last week (0929-1003)?
Weekly Report · 10/06 09:05
Weekly Report: what happened at OPT last week (0922-0926)?
Weekly Report · 09/29 09:05
Weekly Report: what happened at OPT last week (0915-0919)?
Weekly Report · 09/22 09:05
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16 00:21
More
Webull provides a variety of real-time OPTEY stock news. You can receive the latest news about Opthea Ltd through multiple platforms. This information may help you make smarter investment decisions.
About OPTEY
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).